BJMO - volume 13, issue 8, december 2019
K. Papadimitriou MD, M. Peeters MD, PhD, H. Prenen MD, PhD
This report will focus on some of the key studies in the field of digestive oncology, presented during the 2019 annual ESMO meeting. During the congress, many studies were presented from early phase I to large phase III trials. Different approaches to activate the immune system against tumours as well as PARP and CDK4/6 inhibitors were once more at the centre of interest for different types of cancer and settings.
Read moreBJMO - volume 13, issue 6, october 2019
C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, B. Van Den Heuvel MD, K. Papadimitriou MD, M. Rasschaert MD, H. Prenen MD, PhD, M. Peeters MD, PhD
For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.
(BELG J MED ONCOL 2019;13(6):234–239)
Read moreBJMO - volume 12, issue 8, december 2018
B. Van Den Heuvel MD, M. Rasschaert MD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.
Read moreBJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, L. Triest MD, J. Van den Brande , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read moreBJMO - volume 11, issue 7, november 2017
L. Triest MD, K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.
(BELG J ONCOL 2017;11(7):340–348)
Read moreBJMO - volume 11, issue 4, september 2017
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) took place once more in Chicago from June 2 to 6, bringing together more than 30,000 oncology professionals from around the world. This year’s meeting theme is “Making a Difference in Cancer Care with You.” Studies spanning the spectrum of GI cancer prevention and care, from new standards of care to immunotherapy and precision medicine, will be highlighted.
Read moreBJMO - volume 10, issue 5, august 2016
K. Papadimitriou MD, T. Van den Mooter MD, J. Van den Brande , M. Rasschaert MD, M. Peeters MD, PhD
During the 2016 ASCO Annual Meeting, a robust body of phase III trials was presented in the gastrointestinal (GI) oncology field, including updates and interesting post-hoc analyses. Once more, the early phase research was mainly focused on immunotherapy, with some promising results.
(BELG J MED ONCOL 2016;10(5):150–155)
Read more
Top
